January 13, 2015
Fagron Holding USA LLC – 1111 Brickell Ave. Suite 1550 - Miami, FL 33131 - United States
Fagron North America Applauds TRICARE Decision Supporting Access to Compounds
Miami, FL—Fagron North America is praising a decision last week by the TRICARE Uniform Beneficiary Advisory Panel to NOT put into effect a strict prior authorization process for compounded medication therapies. TRICARE is the health care program which serves Uniformed Service members, retirees and their families worldwide.
Compounded medications allow medical practitioners to provide patients with customized, alternative treatment options. Whether the patient has an allergy to certain drug ingredients, requires an alternative dosage form, or needs access to medicine not commercially available, Fagron North America recognizes the everyday need of compounded medications for members of our Armed Forces.
“Our men and women in uniform put their lives on the line every day for our country. These heroes, and their families, deserve access to the best possible medical treatments available,” said Jake Jackson, President. “Fagron North America is encouraged that the Panel recognized the need to provide access to compounded medications for military families without an additional administrative burden for practitioners and payers. Fagron is committed to continue its work as a leading stakeholder in ensuring continued access to compounded medications.”
About Fagron North America
Fagron North America is a group of innovative, scientific pharmaceutical companies that focus on optimizing and innovating pharmaceutical compounding across the U.S. Fagron North America is a leading supplier of pharmaceutical raw materials, equipment and supplies, concepts and compounded medications to hospital pharmacies and patients. Fagron North America is fully integrated with significant capabilities in research, development, manufacturing and distribution. Fagron North America is headquartered in Miami, Florida.
Fagron North America